STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem 

AI Summary

Alnylam's growth relies heavily on Amvuttra, its heart-disease drug, but sales have been slowing. The company faces pressure to address this performance as it pursues significant growth ambitions.

Alnylam is heavily dependent on its heart drug Amvuttra for growth — and sales have been slowing.